| 28.82 -0.35 (-1.2%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.73 | 1-year : | 47.58 |
| Resists | First : | 34.87 | Second : | 40.73 |
| Pivot price | 30.15 |
|||
| Supports | First : | 26.32  |
Second : | 21.04 |
| MAs | MA(5) : | 30.79 |
MA(20) : | 29.24 |
| MA(100) : | 25.39 |
MA(250) : | 19.37 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 36.4 |
D(3) : | 53.6 |
| RSI | RSI(14): 52 |
|||
| 52-week | High : | 38.32 | Low : | 2.45 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DMRA ] has closed above bottom band by 28.7%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.05 - 30.25 | 30.25 - 30.42 |
| Low: | 27.92 - 28.19 | 28.19 - 28.41 |
| Close: | 28.44 - 28.81 | 28.81 - 29.1 |
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Wed, 22 Jul 2026
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Wed, 22 Jul 2026
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Wed, 22 Jul 2026
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Wed, 22 Jul 2026
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
Fri, 17 Jul 2026
Damora Therapeutics completes redomestication to Cayman Islands By Investing.com - Investing.com South Africa
Fri, 17 Jul 2026
Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 91.3 (%) |
| Shares Short | 3,570 (K) |
| Shares Short P.Month | 1,400 (K) |
| EPS | -2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -11.63 |
| PEG Ratio | 0 |
| Price to Book value | 4.58 |
| Price to Sales | 0 |
| Price to Cash Flow | -71.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|